Lv11
30 积分 2023-10-10 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2小时前
已完结
T-cell Engagers in Prostate Cancer
10天前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
12天前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
13天前
已完结
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
21天前
已完结
Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer
1个月前
已完结
Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability
1个月前
已完结
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework
1个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2个月前
已完结
Peptides Unplugged: Small Chains Tackling Big Challenges—One Life-Saving Sequence at a Time!
2个月前
已完结
皖公网安备34019202002308
